ISDA: 5V19

Deposition Date 2017-03-01

Release Date 2017-03-29

Last Version Date 2024-03-06

Entry Detail

PDB ID:

5V19

Keywords:

TRANSFERASE/TRANSFERASE INHIBITOR

Title:

Structure-based drug design of novel ASK1 inhibitors using a fully integrated lead optimization strategy

Biological Source:

Source Organism(s):

Homo sapiens (Taxon ID: 9606)

Expression System(s):

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

3.10 Å

R-Value Free:

0.28

R-Value Work:

0.23

R-Value Observed:

0.24

Space Group:

P 65 2 2

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Mitogen-activated protein kinase kinase kinase 5
Gene (Uniprot):MAP3K5
Chain IDs:A, B
Chain Length:271
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:Q99683 Pfam ID:PF00069 EC:2.7.12.2

Ligand Molecules

8V4

Primary Citation

Structure-based drug design of novel ASK1 inhibitors using an integrated lead optimization strategy.

Gibson, T.S, Johnson, B, Fanjul, A, Halkowycz, P, Dougan, D.R, Cole, D, Swann, S.Show

Bioorg. Med. Chem. Lett. 27 1709 1713 (2017)

PMID: 28291695 DOI: 10.1016/j.bmcl.2017.02.079

Abstact

Structure-based drug design is an iterative process that is an established means to accelerate lead optimization, and is most powerful when integrated with information from different sources. Herein is described the use of such methods in conjunction with deconstruction and re-optimization of a diverse series of ASK1 chemotypes along with high-throughput screening that lead to the identification of a novel series of efficient ASK1 inhibitors displaying robust MAP3K pathway inhibition.

Legend

Protein

Chemical

Disease

Primary Citation of related structures

Abstact

Feedback Form